In vitro antimicrobial activities and therapeutic effect of cefpiramide (SM-1652) on respiratory tract infections

Ktkuo Onuma, Seiichi Aonuma, Akira Watanabe, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno

    Research output: Contribution to journalArticlepeer-review

    Abstract

    From the results of in vitro tests, cefpiramide (CPM, SM-1652) was shown to be active against patient's strains of at least 2 species, S. aureus and P. aeruginosa. Twelve patients of respiratory tract infections were treated with 2 g a day of cefpiramide. Clinical responses were excellent in 6 cases, good in 4 and poor in 2. As for side effects, exanthema, discomfort of the chest and discomfort of the lower extremities were observed in 1 case each. Elevation of transaminases was seen in 4 cases.

    Original languageEnglish
    Pages (from-to)229-232
    Number of pages4
    JournalChemotherapy
    Volume31
    DOIs
    Publication statusPublished - 1983 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'In vitro antimicrobial activities and therapeutic effect of cefpiramide (SM-1652) on respiratory tract infections'. Together they form a unique fingerprint.

    Cite this